DMKJ
CHRS icon

David M. Knott Jr’s Coherus Oncology CHRS Stock Holding History

David M. Knott Jr’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-106,185
Closed -$254K – 101
2024
Q1 		$254K Sell
106,185
-420,127
-80% -$1.03M 0.09% 61
2023
Q4 		$1.75M Sell
526,312
-103,688
-16% -$278K 0.67% 24
2023
Q3 		$2.36M Buy
630,000
+384,990
+157% +$1.78M 0.9% 18
2023
Q2 		$1.05M Buy
+245,010
New +$1.45M 0.42% 41
2023
Q1 		– Sell
-128,517
Closed -$1.02M – 156
2022
Q4 		$1.02M Sell
128,517
-71,483
-36% -$550K 0.38% 44
2022
Q3 		$1.92M Buy
200,000
+13,866
+7% +$140K 0.81% 27
2022
Q2 		$1.35M Buy
186,134
+68,579
+58% +$596K 0.57% 43
2022
Q1 		$1.52M Buy
117,555
+15,000
+15% +$191K 0.48% 50
2021
Q4 		$1.64M Buy
+102,555
New +$1.79M 0.56% 45

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return